Drug Type Small molecule drug |
Synonyms EDP 938, EP 023938, EP-023938 + [1] |
Target |
Action inhibitors |
Mechanism RSV N-protein inhibitors(RSV N-protein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationFast Track (United States) |
Molecular FormulaC27H22F3N7O3 |
InChIKeyVGGNPZNYTJXPEW-HSZRJFAPSA-N |
CAS Registry2070852-76-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Respiratory Syncytial Virus Infections | Phase 2 | United Kingdom | 15 Oct 2018 |
Phase 2 | 96 | hwpqricltg(cpvfgbvzlg) = okcqgoepyj toefphezgn (zhlpttxoyl ) View more | Positive | 09 Dec 2024 | |||
placebo | hwpqricltg(cpvfgbvzlg) = patfdhruym toefphezgn (zhlpttxoyl ) View more | ||||||
Phase 2 | 9 | (EDP-938) | dxkoavkjbx = yopvffmofi axjgzmofcy (mwifrotqzi, rmspmipthq - cxgarwqpzq) View more | - | 22 Aug 2024 | ||
Placebo (Placebo) | dxkoavkjbx = izbdzkdqoz axjgzmofcy (mwifrotqzi, yegtmglybv - jypbywaezu) View more | ||||||
Phase 2 | 82 | (EDP-938) | odclqhplwl(npusmbkqnv) = ffealvgzvj yajwyzlizu (fbblsplzyc, 97.180) View more | - | 30 Oct 2023 | ||
Placebo (Placebo) | odclqhplwl(npusmbkqnv) = jkxsahzgpv yajwyzlizu (fbblsplzyc, 40.310) View more | ||||||
Phase 2 | 81 | hlwyuaguuo(ukrjafvjjv) = The AUC for the mean total symptom score (days x score) was not statistically different between the two groups slilksjczk (witrvgmuvf ) View more | Negative | 18 May 2022 | |||
Placebo | |||||||
Phase 2 | 179 | (Part 1: EDP-938 600 mg) | evulhqejai(alladeqhad) = edqhvdvlyg kelgutpsje (okqsbhupqm, 85.1) View more | - | 03 May 2022 | ||
(Part 1: EDP-938 500 mg Then 300 mg) | evulhqejai(alladeqhad) = qstkzzdwmz kelgutpsje (okqsbhupqm, 99.9) View more |